Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA. – Business Wire (press release)
|
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA.
Business Wire (press release) THINK (THerapeutic Immunotherapy with NKR-2) is a multinational (EU/US) open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR–T NKR-2 cells in seven refractory cancers, including five solid … |
